Related Experiment Videos
[Study of the DNCB skin test in patients with solid neoplasms]
Archivio Per Le Scienze Mediche
|July 1, 1978
Summary
The DNCB skin test revealed a link between a negative response and increased mortality in solid tumor patients. This immune response correlated with specific blood chemistry changes, indicating potential prognostic value.
Area of Science:
- Immunology
- Oncology
- Clinical Chemistry
Background:
- Cell-mediated immunity plays a crucial role in cancer progression.
- Assessing immune status in cancer patients can offer prognostic insights.
- The DNCB skin test is a method to evaluate delayed-type hypersensitivity responses.
Purpose of the Study:
- To investigate the prognostic significance of the DNCB skin test in patients with solid tumors.
- To explore correlations between DNCB skin test responses and specific blood chemistry parameters.
Main Methods:
- Conducted the DNCB (2,4-dinitrochlorobenzene) skin test on 47 solid tumor patients.
- Monitored patient mortality and recorded DNCB test responses (positive or negative).
- Analyzed blood samples for key chemistry parameters including IgG, PCR, albumin/globulin ratio, and lymphocyte counts.
Main Results:
- A higher mortality rate was observed in patients with a negative DNCB skin test response compared to positive responders (15 deaths vs. 1/24).
- Negative DNCB responses were statistically associated with elevated IgG levels.
- Negative DNCB responses correlated with positive PCR (polymerase chain reaction) results, inverted albumin/globulin ratio, and decreased peripheral lymphocyte counts.
Conclusions:
- The DNCB skin test may serve as a prognostic indicator in solid tumor patients.
- Immune status, as assessed by DNCB testing, is linked to specific hematological and biochemical markers.
- Further research is warranted to elucidate the clinical utility of DNCB testing in cancer management.